Article

Acuity, Froptix, eXegenics sign merger

Miami-Acuity Pharmaceuticals, Froptix Corp., and eXegenics Inc. have inked a merger agreement to unite the three companies under one corporation to be named Opko Corp. The new company will be headquartered in Miami.

Miami-Acuity Pharmaceuticals, Froptix Corp., and eXegenics Inc. have inked a merger agreement to unite the three companies under one corporation to be named Opko Corp. The new company will be headquartered in Miami.

Acuity’s products include the gene-silencing agent bevasiranib (formerly Cand5), which successfully has completed phase II clinical trials for wet age-related macular degeneration (AMD) and diabetic macular edema; a product for conjunctivitis in phase I clinical development; and a line-up of preclinical treatments for serious ophthalmic conditions. Froptix has numerous molecules in development to treat dry AMD and other ophthalmic diseases. The new company also plans to create diagnostic products.

The Frost Group, a private equity firm, plans to loan the new company $12 million. Part of this credit line will finance the transition and part, along with $16 million in cash held by eXegenics, will finance other initiatives, including the company’s planned phase III trial of bevasiranib as an ongoing therapy for wet AMD in combination with ranibizumab injection (Lucentis, Genentech).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.